Galectin Therapeutics Q2 loss widens

Galectin Therapeutics

14/08/2026 13:17

Overview
U.S. liver disease drug developer's Q2 net loss per share widened yr/yr
Company converted $105.8 mln in debt to common stock, strengthening balance sheet
Research and development expenses fell due to timing of NAVIGATE trial expenditures

Outlook
Company expects to submit Phase 3 belapectin trial protocol in advanced MASH cirrhosis in 3Q 2026
Galectin believes it has sufficient cash to fund planned operations through June 2027

Result Drivers
R&D EXPENSES - Research and development costs decreased due to timing of expenditures related to the NAVIGATE clinical trial
DERIVATIVE LIABILITY CHARGE - Net loss increased mainly due to a $3.2 mln charge for change in fair value of derivative liabilities
G&A EXPENSES - General and administrative expenses rose due to increased non-cash, stock-based compensation

Company press release: ID:nGNX6L8ptY

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.14
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Galectin Therapeutics Inc is $11.00, about 211.6% above its August 13 closing price of $3.53

Reuters Recommended Reads
Aug 13 - CAMP4 Therapeutics Q2 loss per share misses estimates on non-cash derivative charge
Aug 13 - Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Aug 14 - Acurx Pharmaceuticals Q2 loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)